Conventional chemotherapy has been unsuccessful in inhibiting chemoresistance and bladder cancer progression along with adverse side effects, mainly due to off-target drug distribution. Therefore, new drug delivery strategies, new therapies and therapies or combinations thereof are being explored to develop better therapeutics. At Alfa Cytology, we enable help our clients develop novel drug delivery system for bladder cancer.

Introduction to Urease-Powered Nanomotor

Bladder cancer is a prevalent and challenging disease that affects a significant number of individuals worldwide. It is characterized by the abnormal growth of cells in the bladder lining, leading to the formation of tumors. The therapy of bladder cancer often involves a combination of surgery, radiation therapy, chemotherapy, and immunotherapy. However, these therapeutic modalities have their limitations and can be associated with adverse side effects.

Fig 1. Therapies and nano drug delivery systems for bladder cancer. (Choi H., et al. 2020)

In recent years, there has been a growing interest in developing innovative drug delivery systems that can enhance the effectiveness of bladder cancer therapy while minimizing systemic toxicity. These systems aim to deliver therapeutic agents directly to the tumor site, thereby maximizing local drug concentration and minimizing drug exposure to healthy tissues. The development of such drug delivery systems holds great promise for improving the outcomes of bladder cancer.

Our Services

At Alfa Cytology, we are at the forefront of drug delivery systems development for bladder cancer. Our team of highly skilled researchers and scientists is dedicated to advancing the field of targeted therapy for bladder cancer. Our comprehensive service encompasses various aspects of drug delivery system development, including:

Contact Us

At Alfa Cytology, we specialize in developing drug delivery systems that facilitate advanced therapies for bladder cancer. If you would like to learn more about our services or discuss potential collaborations, please contact us today to explore the possibilities of this innovative approach in bladder cancer therapy.

• AI & Computational Powered Drug Discovery
• Mechanism of Action (MOA) Studies for Bladder Cancer
• Targets Identification for Bladder Cancer
• Targets Validation for Bladder Cancer
• Cell Membranes-Based Delivery System Development
• Chitosan-Based Delivery System Development
• Extracellular Vesicles-Based Delivery System Development
• Gel-Based Delivery System Development
• Liposomal Delivery System Development
• Metal Nanoparticles-Based Delivery System Development
• Microemulsion-Based Delivery System Development
• MSNP-Based Delivery System Development
• Polymeric Micelles Delivery System Development
• Urease-Powered Nanomotor Delivery System Development